Express News | Journey Medical Corp - Initial Supply of Emrosi Expected in Q1 or Q2 2025
Express News | Journey Medical Corporation Announces U.S. FDA Approval of Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 Mg) for the Treatment of Rosacea
Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 31%
Highbridge Capital Management's Strategic Acquisition of Fortress Biotech Shares
Express News | Highbridge Capital Management, LLC Reports 9% Passive Stake in Fortress Biotech, Inc. as of Sept 30 - SEC Filing
Mustang Bio Announces Exercise of Warrants for $4 Million Gross Proceeds